Merck Serono, a division of Merck, and Auxogyn have partnered to develop Early Embryo Viability Assessment (Eeva) test.
Pursuant to the deal, Merck Serono will provide strategic, scientific and medical support for the development of the Eeva test, which can fit into nearly all embryo incubators.
The test leverages computer vision software to generate laboratory based measurements that aid in the evaluation of embryo development.
Auxogyn president and chief executive officer Lissa Goldenstein said, "We hope that the Eeva Test will provide fertility clinics with access to a non-invasive computerized test that can help with decision making in the embryo selection process."
Auxogyn Eeva test won CE mark in July 2012 while a 510(k) application for the test submitted to the FDA is still under review.
Merck Serono global drug development and medical head, executive vice president Dr. Annalisa Jenkins said the company's objective is to invest in science, medicines and technologies that deliver improved outcomes to patients throughout the IVF process.
"Therefore, we are very pleased to be collaborating with Auxogyn to further support the clinical development of their Eeva Test technology," Dr. Jenkins added.